Spain Antibacterial (Antibiotics) Drugs Market Report 2022 to 2030

Spain Antibacterial (Antibiotics) Drugs Market Analysis

$ 3999

Spain Antibacterial (Antibiotics) Drugs Market is at around $0.98 Bn in 2023 and is projected to reach $1.23 Bn in 2030, exhibiting a CAGR of 3.2% during the forecast period. The market is being driven by the aging population, rising healthcare expenditures, and an increase in the incidence of bacterial infections. The market is dominated by key players like Almirall, Laboratorios Farmacéuticos del Dr. Esteve, Pfizer, Roche, Novartis, GlaxoSmithKline (GSK), Abbott Laboratories, Johnson & Johnson, Merck & Co., Inc., and Sanofi S.A.

ID: IN10ESPH005 CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Aneri Parekh

Buy Now

Spain Antibacterial (Antibiotics) Drugs Market Executive Summary

Spain Antibacterial (Antibiotics) Drugs Market is at around $0.98 Bn in 2023 and is projected to reach $1.23 Bn in 2030, exhibiting a CAGR of 3.2% during the forecast period.

The manufacturing, supply, and use of antibiotic drugs in Spain by the pharmaceutical industry are all a part of Spain Antibiotics Market. It represents the dynamics of supply and demand, legal frameworks, and trends influencing the nation's use of antibiotics. Players in the market seek to treat bacterial illnesses effectively while addressing issues including antibiotic resistance and changing health care regulations. To address public health problems and ensure the responsible use of antibiotics, the market landscape entails collaboration between pharmaceutical companies, healthcare providers, regulatory bodies, and research organizations.

The market for antibiotics in Spain is expanding steadily, propelled by rising healthcare costs and the incidence of infectious illnesses. Major businesses in the industry are concentrating on R&D to bring forth cutting-edge antibiotic treatments. The commercial environment is being shaped by government programs meant to fight antimicrobial resistance and encourage responsible use of antibiotics.

In recent years, there has been a notable shift in the antibiotic industry. The market is anticipated to expand after bringing in $50.91 Bn in revenue in 2023. The primary causes of this expansion are the creation of new products and the rise in infectious diseases. The necessity for fresh antimicrobial formulations, increased research and development, and antibiotic prescriptions have all contributed to these advancements. Market expansion is impacted by new antibiotics and urbanization.

The Spanish pharmaceutical company Almirall is becoming a more prominent player in the market for antibiotics. Wynzora (ceftaroline), which was introduced in 2022, targets resistant Gram-positive bacteria and by the end of the year, had a double-digit market share in Spain. Seysara (sarecycline), which was introduced in 2018, is primarily intended for treating acne and has taken a 6% market share in the oral antibiotic market.

Spain antibacterial (antibiotics) drugs market

Market Dynamics

Market Growth Drivers:

Growing Incidence of Bacterial Infections: As a result of growing urbanization and population growth, bacterial infections are becoming more common. The need for antibiotics in both community and hospital settings is fuelled by this.

Growing Healthcare Expenditure: Consumers are more willing and able to spend money on healthcare, particularly antibiotics, as the economy grows and healthcare infrastructure evolves. This helps the market expand.

Aging Population: Spain's population is aging with 9.68 Mn people aged over 65 in 2023. Due to their increased susceptibility to infections, the elderly have a greater need for antibiotics to treat bacterial illnesses.

Market Restraints:

Regulatory Framework: Governmental organizations, the Spanish Agency of Medicines and Medical Devices (AEMPS), control the use and sale of antibiotics. Tight laws governing the distribution, prescription, and approval of antibiotics can make it difficult for new products to enter the market.

Competition from Generics: Similar to many other nations, Spain is witnessing a sharp expansion in the market for generic antibiotics. As a result, brand-name antibiotic prices are under pressure, which makes it harder for producers to turn a profit.

Notable Recent Updates

June 2023, Venus Remedies Ltd., a prominent pharmaceutical company, was successful in obtaining marketing permission from Spain for their generic antibiotic Meropenem. After launching the medicine in December 2023, they were able to secure a 10% portion of the meropenem market in Spain, which was valued at $6.34 Mn

Healthcare Policies and Regulatory Landscape

The regulatory agency that authorizes the marketing of all pharmaceuticals in Spain is the Spanish Agency of Medicines and Medical Devices (AEMPS). To obtain the drug's marketing authorization in Spain, the applicant submits a dossier containing all required data to the AEMPS. In addition, the applicant simultaneously submits applications for approval to many EU member states. It is necessary to coordinate with the European Medicines Agency (EMA) and other EU members. Harmonizing regulatory standards throughout the EU adds to the complexity.

Competitive Landscape

Key Players:

Almirall
Laboratorios Farmacéuticos del Dr. Esteve
Pfizer
Roche
Novartis
GlaxoSmithKline (GSK)
Abbott Laboratories
Johnson & Johnson
Merck & Co., Inc.
Sanofi S.A.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Spain Antibacterial (Antibiotics) Drugs Market Segmentation

By Drug Class

Cephalosporins
Penicillin
Fluoroquinolone
Macrolides
Carbapenems
Aminoglycosides
Sulfonamides
7-ACA
Others

By Type

Branded Antibiotics
Generic Antibiotics

By Action Mechanism

Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
DNA Synthesis Inhibitors
RNA Synthesis Inhibitors
Mycolic Acid Inhibitors
Others

By Spectrum

Broad-spectrum Antibiotic
Narrow-spectrum Antibiotic

By Administration

Oral
Intravenous
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.